Science | ABNewswire

Ecosense Expands First-of-Its-Kind Radon Library Lending Program Across Pennsylvania

Industry Leader Partners with Local Libraries in One of the Nation’s Highest-Risk Radon States. Pittsburgh, PA – August 26th, 2025 – Ecosense, an industry-leading provider of the best home radon detector available on the market, is delighted to announce the … Continue reading →

Next-Level AI in French: ChatGPT Français Launches Web and Image Integration

From live web search to image understanding, ChatGPT Français introduces powerful new features to redefine AI conversations for French-speaking users. Artificial intelligence is no longer a futuristic concept—it is a daily companion that informs, assists, and enhances the way we … Continue reading →

Chance AI Brings Its Curiosity Lens to Android After Two Product Hunt #1

New York – August 25, 2025 – New York–based startup Chance, the first true AI Visual Agent app, officially released Chance AI: Curiosity Lens on Android on August 19, 2025 (00:00 ET). With this launch, the first AI Visual Agent … Continue reading →

Advanced Ovarian Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Advanced Ovarian Cancer Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Acute Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Acute Myeloid Leukemia Pipeline Insight” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and nonclinical … Continue reading →

Glaucoma Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Glaucoma Pipeline Insight, 2025,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma pipeline landscape. It covers the Glaucoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glaucoma pipeline therapeutics … Continue reading →

Limbal Stem Cell Deficiency Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Limbal Stem Cell Deficiency Pipeline Insight, 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Limbal Stem Cell Deficiency pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also … Continue reading →

Immune Thrombocytopenia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Immune Thrombocytopenia Pipeline Insight, 2025,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Immune Thrombocytopenia (ITP) pipeline landscape. It covers the Immune Thrombocytopenia pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Hereditary Angioedema Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Hereditary Angioedema Pipeline Insight, 2025,” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Advanced Kidney Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight’s, “Advanced Kidney Cancer Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the Advanced Kidney Cancer pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Monday - March 30, 2026

Category Archives: Science